Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17031570 | 0.89 | CNR2 (0.53) | CNR2SLC2A1BTKPOLB | |
| SCHEMBL15615888 | 0.85 | LMNA (0.53) | POLB | |
| SCHEMBL15615899 | 0.81 | MTOR (0.46) | CNR2SLC2A1BTK | |
| SCHEMBL15615876 | 0.80 | MPO (0.51) | CYP1A2CYP2C9CYP3A4AKR1C3AKR1C2 | |
| SCHEMBL15615882 | 0.80 | MAPT (0.52) | — | |
| SCHEMBL16804753 | 0.75 | MTOR (0.43) | APP | |
| SCHEMBL16086165 | 0.74 | IDH2 (0.44) | APP | |
| SCHEMBL5083313 | 0.73 | CNR2 (1.00) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL14978436 | 0.73 | CTSC (0.44) | APPPOLB | |
| SCHEMBL28821019 | 0.72 | CTSC (0.45) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2896622-B1 | PI3K AND/OR MTOR INHIBITOR | XUANZHU PHARMA CO LTD (CN) | 2017-05-03 | — | — | EP | disclosed |
| EP-2896622-B1 | PI3K AND/OR MTOR INHIBITOR | XUANZHU PHARMA CO LTD (CN) | 2017-05-03 | — | — | EP | disclosed |
| US-9365572-B2 | PI3K and/or mTOR inhibitor | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-14 | — | — | US | disclosed |
| US-9365572-B2 | PI3K and/or mTOR inhibitor | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-14 | — | — | US | disclosed |
| US-20150239885-A1 | PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-08-27 | — | — | US | disclosed |
| US-20150239885-A1 | PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-08-27 | — | — | US | disclosed |
| EP-2896622-A1 | PI3K AND/OR MTOR INHIBITOR | Xuanzhu Pharma Co., Ltd. (CN) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014154026-A1 | PI3K AND/OR mTOR INHIBITOR PRODRUG | 山东轩竹医药科技有限公司 (CN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014040373-A1 | PI3K AND/OR MTOR INHIBITOR | 山东轩竹医药科技有限公司 (CN) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239885-A1 | PI3K AND/OR MTOR INHIBITOR | MTOR, RICTOR, RPTOR | CNR2 1868/4885SLC2A1 1158/4885RECQL 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.